国际眼科纵览 ›› 2012, Vol. 36 ›› Issue (4): 228-234.doi: 10 3760/ cma. j. issn. 16735803 2012 04 003

• 综述 • 上一篇    下一篇

抗血管内皮生长因子药物治疗糖尿病视网膜病变的研究现状

翟怡 朱亚楠 姚克   

  1. 310009 杭州,浙江大学医学部附属第二医院眼科中心
  • 收稿日期:2012-05-18 出版日期:2012-08-22 发布日期:2012-09-03
  • 通讯作者: 姚克,Email: xlren@zju.edu.cn E-mail:xlren@zju.edu.cn

Clinical research progress of antiVEGF agents for diabetic retinopathy

ZHAI Yi, ZHU Ya-nan, YAO Ke   

  1. Eye Center of the 2nd Affiliated Hospital, Medical College of Zhejiang University, Hangzhou 310009, China
  • Received:2012-05-18 Online:2012-08-22 Published:2012-09-03
  • Contact: YAO Ke, Email: xlren@zju.edu.cn E-mail:xlren@zju.edu.cn

摘要: 糖尿病可引起眼内血管内皮生长因子(vascular endothelial growth factor, VEGF)水平病理性升高,导致眼内新生血管形成、黄斑水肿的发生。抗VEGF药物最早被用于湿性年龄相关性黄斑变性,现也被试验性地用于糖尿病视网膜病变(diabetic retinopathy,DR)。VEGF165选择性拮抗剂Pegaptanib与VEGFA单抗Ranibizumab被批准玻璃体内注射,且对DR有较好的疗效;VEGFA全长抗体Bevacizumab被标示外用于玻璃体内注射治疗DR,也能达到较好的效果;重组融合蛋白Aflibercept针对DR的疗效也得到一些试验的支持。玻璃体内注射抗VEGF药物治疗DR已被证实短期有效且安全,但其长期的疗效与安全性有待更多的大规模临床试验来验证。

Abstract: Diabetes mellitus can pathologically elevate ocular vascular endothelial growth factor (VEGE)  level, which causes the angiogenesis and edema in eyes. The extensive use of antiVEGF agents for the agerelated macular degeneration (AMD) has prompted research into the application of antiVEGF drugs for the diabetic retinopathy (DR). Pegaptanib and ranibizumab, which are approved for intravitreal injection, have shown shortterm effect on visual acuity improvement. And offlabel intravitreal use of bevacizumab has shown shortterm positive effects on both visual acuity improvement and central retinal thickness. Aflibercept has also been regarded as an effective treatment to DR, which is supported by trials. The growing evidence indicates that antiVEGF agents are beneficial for the DR treatment, especially the one with diabetic macular edema (DME). Still, physicians expect the results of large, controlled trials to substantiate the longterm efficacy and safety of antiVEGF drugs for DR.